BRD4 degradation blocks expression of MYC and multiple forms of
stem cell resistance in Ph+ chronic myeloid leukemia

J 2022

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia

PETER, Barbara, Gregor EISENWORT, Irina SADOVNIK, Karin BAUER, Michael WILLMANN et. al.

Základní údaje

Originální název

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia

Autoři

Vydání

American Journal of Hematology, Hoboken, John Wiley & Sons, 2022, 0361-8609

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 12.800

Kód RIV

RIV/00216224:14110/22:00127384

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/ajh.26650

UT WoS

000826289800001

Klíčová slova anglicky

chronic myeloid leukemia; stem cell resistance; BRD4 degradation blocks expression; MYC

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 12. 2022 12:35, Mgr. Tereza Miškechová

Anotace

V originále

In most patients with chronic myeloid leukemia (CML) clonal cells can be kept under control by BCR::ABL1 tyrosine kinase inhibitors (TKI). However, overt resistance or intolerance against these TKI may occur. We identified the epigenetic reader BRD4 and its downstream-effector MYC as growth regulators and therapeutic targets in CML cells. BRD4 and MYC were found to be expressed in primary CML cells, CD34(+)/CD38(-) leukemic stem cells (LSC), and in the CML cell lines KU812, K562, KCL22, and KCL22(T315I). The BRD4-targeting drug JQ1 was found to suppress proliferation in KU812 cells and primary leukemic cells in the majority of patients with chronic phase CML. In the blast phase of CML, JQ1 was less effective. However, the BRD4 degrader dBET6 was found to block proliferation and/or survival of primary CML cells in all patients tested, including blast phase CML and CML cells exhibiting the T315I variant of BCR::ABL1. Moreover, dBET6 was found to block MYC expression and to synergize with BCR::ABL1 TKI in inhibiting the proliferation in the JQ1-resistant cell line K562. Furthermore, BRD4 degradation was found to overcome osteoblast-induced TKI resistance of CML LSC in a co-culture system and to block interferon-gamma-induced upregulation of the checkpoint antigen PD-L1 in LSC. Finally, dBET6 was found to suppress the in vitro survival of CML LSC and their engraftment in NSG mice. Together, targeting of BRD4 and MYC through BET degradation sensitizes CML cells against BCR::ABL1 TKI and is a potent approach to overcome multiple forms of drug resistance in CML LSC.

Citovat

PETER, Barbara, Gregor EISENWORT, Irina SADOVNIK, Karin BAUER, Michael WILLMANN, Thomas RUELICKE, Daniela BERGER, Gabriele STEFANZL, Georg GREINER, Gregor HOERMANN, Alexandra KELLER, Dominik WOLF, Martin ČULEN, Georg E WINTER, Thomas HOFFMANN, Ana-Iris SCHIEFER, Wolfgang R SPERR, Johannes ZUBER, Jiří MAYER a Peter VALENT. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia. American Journal of Hematology. Hoboken: John Wiley & Sons, 2022, roč. 97, č. 9, s. 1215-1225. ISSN 0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.26650.

@article{2237999,
   author = {Peter, Barbara and Eisenwort, Gregor and Sadovnik, Irina and Bauer, Karin and Willmann, Michael and Ruelicke, Thomas and Berger, Daniela and Stefanzl, Gabriele and Greiner, Georg and Hoermann, Gregor and Keller, Alexandra and Wolf, Dominik and Čulen, Martin and Winter, Georg E and Hoffmann, Thomas and Schiefer, AnaandIris and Sperr, Wolfgang R and Zuber, Johannes and Mayer, Jiří and Valent, Peter},
   article_location = {Hoboken},
   article_number = {9},
   doi = {http://dx.doi.org/10.1002/ajh.26650},
   keywords = {chronic myeloid leukemia; stem cell resistance; BRD4 degradation blocks expression; MYC},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/ajh.26650},
   volume = {97},
   year = {2022}
}

TY  - JOUR
ID  - 2237999
AU  - Peter, Barbara - Eisenwort, Gregor - Sadovnik, Irina - Bauer, Karin - Willmann, Michael - Ruelicke, Thomas - Berger, Daniela - Stefanzl, Gabriele - Greiner, Georg - Hoermann, Gregor - Keller, Alexandra - Wolf, Dominik - Čulen, Martin - Winter, Georg E - Hoffmann, Thomas - Schiefer, Ana-Iris - Sperr, Wolfgang R - Zuber, Johannes - Mayer, Jiří - Valent, Peter
PY  - 2022
TI  - BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia
JF  - American Journal of Hematology
VL  - 97
IS  - 9
SP  - 1215-1225
EP  - 1215-1225
PB  - John Wiley & Sons
SN  - 03618609
KW  - chronic myeloid leukemia
KW  - stem cell resistance
KW  - BRD4 degradation blocks expression
KW  - MYC
UR  - https://onlinelibrary.wiley.com/doi/10.1002/ajh.26650
N2  - In most patients with chronic myeloid leukemia (CML) clonal cells can be kept under control by BCR::ABL1 tyrosine kinase inhibitors (TKI). However, overt resistance or intolerance against these TKI may occur. We identified the epigenetic reader BRD4 and its downstream-effector MYC as growth regulators and therapeutic targets in CML cells. BRD4 and MYC were found to be expressed in primary CML cells, CD34(+)/CD38(-) leukemic stem cells (LSC), and in the CML cell lines KU812, K562, KCL22, and KCL22(T315I). The BRD4-targeting drug JQ1 was found to suppress proliferation in KU812 cells and primary leukemic cells in the majority of patients with chronic phase CML. In the blast phase of CML, JQ1 was less effective. However, the BRD4 degrader dBET6 was found to block proliferation and/or survival of primary CML cells in all patients tested, including blast phase CML and CML cells exhibiting the T315I variant of BCR::ABL1. Moreover, dBET6 was found to block MYC expression and to synergize with BCR::ABL1 TKI in inhibiting the proliferation in the JQ1-resistant cell line K562. Furthermore, BRD4 degradation was found to overcome osteoblast-induced TKI resistance of CML LSC in a co-culture system and to block interferon-gamma-induced upregulation of the checkpoint antigen PD-L1 in LSC. Finally, dBET6 was found to suppress the in vitro survival of CML LSC and their engraftment in NSG mice. Together, targeting of BRD4 and MYC through BET degradation sensitizes CML cells against BCR::ABL1 TKI and is a potent approach to overcome multiple forms of drug resistance in CML LSC.
ER  -

PETER, Barbara, Gregor EISENWORT, Irina SADOVNIK, Karin BAUER, Michael WILLMANN, Thomas RUELICKE, Daniela BERGER, Gabriele STEFANZL, Georg GREINER, Gregor HOERMANN, Alexandra KELLER, Dominik WOLF, Martin ČULEN, Georg E WINTER, Thomas HOFFMANN, Ana-Iris SCHIEFER, Wolfgang R SPERR, Johannes ZUBER, Jiří MAYER a Peter VALENT. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia. \textit{American Journal of Hematology}. Hoboken: John Wiley \&{} Sons, 2022, roč.~97, č.~9, s.~1215-1225. ISSN~0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.26650.

Podrobný výpis o publikaci